Biocept Inc. (BIOC)

0.275 -0.0112 (-3.913%)

IEX Real-Time Price

February 23, 2018 EST.

NASDAQ Capital Market : Healthcare

Prev Close 0.2862

Price Open 0.28

Volume: 726,249

Avg Volume: 2.21M

Market Cap: 18.71M

P/E Ratio -0.31

52 Wk Range 0.2616-2.75



BIOC Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-01-31
67.51M
2.93M
1.41
4.33%

2018-01-12
29.73M
2.48M
4.28
8.34%

2017-12-29
29.73M
2.7M
2.17
9.07%

2017-12-15
29.73M
2.64M
2.10
8.87%




BIOC Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-03-06
Q4 2017
N/A
-0.19 (1)
0.00
0.00

2017-11-09
Q3 2017
AMC
-0.19 (2)
-0.20
-0.01

2017-08-10
Q2 2017
AMC
-0.20 (2)
-0.21
-0.01

2017-05-11
Q1 2017
AMC
-0.22 (1)
-0.21
0.01

News

Biocept Receives Additional Patent Issuances in Three Major International Territories for its Target Selector Platform (2018-02-05 08:05 PR Newswire)

SAN DIEGO , Feb. 5, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the issuance of patents in…

 

Biocept Announces Closing of $14.8 Million Public Offering of 32,854,606 Shares of Common Stock and Warrants to Purchase 32,854,606 Shares of Common Stock (2018-01-30 16:05 PR Newswire)

SAN DIEGO , Jan. 30, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer,…

 

Biocept Comments on Updated Consensus Medical Guidelines Recommending Liquid Biopsy for Profiling of Tumor Biomarkers to Assist with the Treatment of Patients with Lung Cancer (2018-01-30 08:05 PR Newswire)

SAN DIEGO , Jan. 30, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, comments on the recently upd…

 

Biocept prices equity offering at $0.45; shares down 19% premarket (2018-01-26 06:52 SeekingAlpha)

Biocept (NASDAQ: BIOC ) is down 19% premarket on modestly higher volume in response to its public offering of common stock and warrants at a combined price of $0.45. Specifically, the offering is 33,333,333 shares of stock and accompanying five-year warrants to purchase up to 3…

 

Biocept Announces Pricing of $15.0 Million Public Offering of 33,333,333 Shares of Common Stock and Warrants to Purchase 33,333,333 Shares of Common Stock (2018-01-26 06:31 PR Newswire)

SAN DIEGO , Jan. 26, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer,…

 

Biocept Study Shows Incorporation of Thermo Fisher QuantStudio 5 PCR Instrument into Target Selector Platform Improves Sensitivity and Specificity in Detection of Lung Cancer Biomarkers (2018-01-09 08:05 PR Newswire)

SAN DIEGO , Jan. 9, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that incorporati…

 


Statistics

Shares Outstanding: 68.04M

Top 15 Institution Percent: 15.90

Price To Sales: 4.78

Price To Book: 4.84

Revenue: 5.37M

Gross Profit: -3519651

Cash: 34.53M

Debt: 10.69M

Return On Assets: -276.78

Return On Equity: 5496.44

Profit Margin: N/A

Price History

Beta: 2.26

50-day Moving Avg: 0.55

200-day Moving Avg: 1.06

YTD Change: -60.71

5-day Change: -11.15

1-month Change: -58.96

3-month Change: -55.44

6-month Change: -75.45

1-year Change: -86.32

Revenue Per Share: 0.00

Revenue Per Employee: 73493.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Biocept Inc.

Exchange: NASDAQ Capital Market

Industry: Medical Diagnostics & Research

Sector: Healthcare

Website: http://www.biocept.com

Biocept Inc is an early commercial-stage molecular oncology diagnostics company. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample.